Showing results (1-10 of 2,059) with videos related to

Sort By:
Pageof 206
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1993
[Pharmacodynamics of anticancer agents]T Ohtsu, Y Sasaki
Japanese Journal of Clinical Oncology|October 14, 1998
Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposideT Ohtsu, Y Sasaki, T Igarashi, et al.
British Journal of Cancer|January 1, 1997
Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectationsK Itoh, Y Sasaki, H Fujii, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1995
Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusionT Ohtsu, Y Sasaki, T Tamura, et al.
Clinical Pharmacology and Therapeutics|December 2, 1998
Indirect-response model for the time course of leukopenia with anticancer drugsH Minami, Y Sasaki, N Saijo, et al.
Investigational New Drugs|April 9, 2001
Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11T Miya, T Goya, H Fujii, et al.
Japanese Journal of Clinical Oncology|December 1, 1995
The confusion associated with breast cancer chemotherapy in Japan: the first year's experience at the Division of Oncology and Hematology, National Cancer Center Hospital EastT Ohtsu, Y Sasaki, H Fujii, et al.
Cancer Chemotherapy and Pharmacology|June 10, 1998
Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in womenT Ohtsu, H Fujii, H Wakita, et al.
International Journal of Hematology|January 14, 1999
Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphomaK Itoh, T Igarashi, T Ohtsu, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in JapanK Itoh, Y Sasaki, Y Miyata, et al.
Pageof 206